Figure 4: Tumour microenvironment and neovasculature
Tumour endothelium plays a part in engendering spatially-limited immunoresistant niches by expressing the FasL ligand, which kills effector CD8 T cells, and also byposing as a physical barrier to prevent extravasation into the tumour parenchyma. Furthermore, tolerogenic cell types and immunosuppressive molecules present inthe tumour microenvironment and metabolic competition for nutrients have been shown to induce exhaustion and inactivation of CD8 T-cell infiltrates, therebylimiting the durability of immune checkpoint inhibition.
Fas=apoptosis antigen 1. FasL=ligand for FAS receptor. Treg=regulatory T cell.
Tumour endothelium plays a part in engendering spatially-limited immunoresistant niches by expressing the FasL ligand, which kills effector CD8 T cells, and also byposing as a physical barrier to prevent extravasation into the tumour parenchyma. Furthermore, tolerogenic cell types and immunosuppressive molecules present inthe tumour microenvironment and metabolic competition for nutrients have been shown to induce exhaustion and inactivation of CD8 T-cell infiltrates, therebylimiting the durability of immune checkpoint inhibition.
Fas=apoptosis antigen 1. FasL=ligand for FAS receptor. Treg=regulatory T cell.